Nasdaq:ORGO
Organogenesis Holdings Inc.
A biotechnology leader utilizing 3D bioprinting to manufacture life-saving human tissues like skin and cartilage for regenerative medicine applications.
Key Metrics
Investment Thesis
Bull Case
Organogenesis represents a compelling growth opportunity given its proven product pipeline and the expanding addressable market in regenerative medicine. The company's substantial cash position of $93.7M provides ample runway to fund R&D and commercialization without immediate need for dilutive equity financing. Recent profitability suggests the business model is maturing, offering potential for significant upside as new products enter the market.
Bear Case
Despite recent gains, the company still reports negative operating cash flow, raising concerns about its ability to sustain growth without external funding or major revenue expansion. The heavy reliance on a small number of blockbuster products creates concentration risk if any face safety issues or lose patent protection. Valuation multiples may be stretched given the high volatility typical of biotech firms dependent on future clinical milestones.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. (ORGO) is a leading biotechnology company specializing in regenerative medicine, serving hospitals and clinics primarily in the United States with its proprietary Organovo® 3D bioprinting technology. The company manufactures biological tissues such as skin for burn victims, cartilage for joint repair, and corneal cells to treat blindness, leveraging its unique intellectual property to address unmet medical needs. With a significant jump in revenue and net income recently, the firm continues to scale its commercial operations while maintaining substantial cash reserves.
Analysis
Management Discussion
Financial performance in the latest period showed robust growth, with revenue reaching $564.2M compared to $482.0M the prior year, reflecting strong commercial adoption of its tissue products. Net income surged to $37.0M from a mere $0.9M previously, driven by improved operational leverage and cost efficiencies despite ongoing investment in R&D of $44.5M. However, investors should note that cash flow from operations remains negative at -$10.3M, indicating continued heavy capital expenditure requirements for manufacturing expansion.
Industry Overview
The regenerative medicine industry is experiencing rapid expansion as advancements in biofabrication enable the production of complex human tissues for therapeutic use. Regulatory frameworks are evolving to support novel cell and tissue products, creating a favorable environment for innovators with clear pathways to market. Competition is intensifying as traditional pharmaceutical giants enter the space, driving a need for differentiated technologies and strong intellectual property positions.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $450.9M | $433.1M | $482.0M | $564.2M |
| Cost of Revenue | $105.0M | $106.5M | $115.7M | $0 |
| Gross Profit | $345.9M | $326.7M | $366.3M | $564.2M |
| Operating Expenses | $323.6M | $314.1M | $367.6M | $519.5M |
| Operating Income | $22.3M | $12.5M | $-1.3M | $44.7M |
| R&D | $39.8M | $44.4M | $50.3M | $44.5M |
| G&A | $283.8M | $269.8M | $294.5M | $326.2M |
| Stock-Based Comp | $6.6M | $9.0M | $10.6M | $13.3M |
| D&A | — | — | $13.6M | $15.3M |
| Depreciation | $5.8M | $10.4M | $13.6M | $15.3M |
| Amortization | $4.9M | $4.9M | $3.4M | $3.3M |
| Other OpEx | $0 | $0 | $22.8M | $148.7M |
| Non-Operating Income | $-2.0M | $-2.1M | $-1.5M | $2.3M |
| Interest Expense | $2.0M | $2.2M | — | — |
| Pre-Tax Income | $20.3M | $10.4M | $-2.8M | $47.0M |
| Income Tax | $4.8M | $5.4M | $-3.7M | $9.9M |
| Continuing Ops | $15.5M | $4.9M | $861.0K | $37.0M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $15.5M | $4.9M | $861.0K | $37.0M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $15.5M | $4.9M | $861.0K | $37.0M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $222.6M | $225.0M | $285.9M | $362.2M |
| Cash & Equivalents | $102.5M | $103.8M | $135.6M | $93.7M |
| Accounts Receivable | $89.5M | $82.0M | $109.9M | $217.5M |
| Inventory | $24.8M | $28.3M | $26.2M | $29.6M |
| Prepaid Expenses | $5.1M | $10.5M | $13.7M | $18.4M |
| Other Current Assets | $812.0K | $498.0K | $580.0K | $3.1M |
| Long-Term Assets | $226.8M | $235.0M | $211.9M | $236.5M |
| PP&E (Net) | $102.5M | $116.2M | $89.1M | $103.7M |
| Intangibles | $20.8M | $15.9M | $12.5M | $9.1M |
| Goodwill | $28.8M | $28.8M | $28.8M | $28.8M |
| Operating Leases | $43.2M | $40.1M | $37.1M | $55.7M |
| Other LT Assets | $31.5M | $34.0M | $44.5M | $39.2M |
| Total Assets | $449.4M | $460.0M | $497.9M | $598.7M |
| Current Liabilities | $75.0M | $80.5M | $77.5M | $100.1M |
| Accounts Payable | $32.3M | $30.7M | $28.9M | $31.9M |
| Current Leases | $11.7M | $10.0M | $4.3M | $4.9M |
| Other Current Liab | $4.5M | $9.7M | $4.8M | $13.7M |
| Long-Term Liabilities | $108.7M | $100.9M | $35.1M | $64.7M |
| LT Operating Leases | $41.3M | $19.8M | $25.2M | $22.5M |
| Other LT Liab | $67.4M | $81.1M | $9.9M | $42.2M |
| Total Liabilities | $183.7M | $181.4M | $112.6M | $164.8M |
| Shareholders' Equity | $265.7M | $278.7M | $385.3M | $433.9M |
| Retained Earnings | $-45.3M | $-41.0M | $-40.1M | $-3.1M |
| Total L&E | $449.4M | $460.0M | $497.9M | $598.7M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $15.5M | $4.9M | $861.0K | $37.0M |
| Non-Cash Adjustments | $-19.6M | $13.2M | $-23.8M | $-180.9M |
| Working Capital Changes | $28.9M | $12.7M | $37.1M | $133.5M |
| Cash from Operations | $24.9M | $30.9M | $14.2M | $-10.3M |
| Capital Expenditures | $33.9M | $24.4M | $10.0M | $14.2M |
| Cash from Investing | $-33.9M | $-24.4M | $-10.0M | $-14.2M |
| Share Buybacks | — | — | $25.5M | — |
| Cash from Financing | $-2.2M | $-5.5M | $27.6M | $-17.4M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-11.2M | $1.0M | $31.8M | $-41.8M |
| Beginning Cash | $114.5M | $103.3M | $104.3M | $136.2M |
| Ending Cash | $103.3M | $104.3M | $136.2M | $94.3M |
Frequently Asked Questions
How does Organogenesis Holdings Inc. make money?
The company's revenue is driven by three primary streams: 1) Skin products for burn treatment and wound care, 2) Cartilage products for orthopedic joint repair, and 3) Corneal cell therapies for treating blindness and dry eye conditions. These segments are supported by a portfolio of intellectual property focused on advanced biofabrication platforms.
What are the main risks for ORGO?
The biotechnology sector faces significant uncertainty regarding future clinical trial outcomes and potential delays in regulatory approvals that could impact revenue growth. The company is exposed to reimbursement risk as payers may not fully cover the high cost of advanced regenerative therapies without new evidence of long-term efficacy. Intense competition from large pharmaceutical companies and emerging biotech startups seeking to replicate 3D bioprinting capabilities poses a threat to market share.
What is ORGO's competitive advantage?
Organogenesis possesses a robust patent portfolio protecting its proprietary 3D bioprinting technology, creating a high barrier to entry for competitors. The company benefits from strong regulatory relationships with the FDA due to its successful track record in obtaining approvals for multiple tissue products. Additionally, its diversified product pipeline across different therapeutic areas reduces reliance on a single indication.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.